Sneha Patel

Bristol Myers Squibb
Global Head, Vice President, Cell Therapy Manufacturing
Snehal Patel is the Global Head and Vice President for Cell Therapy Manufacturing for Bristol Myers Squibb (BMS). He leads the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including the two cell therapies recently launched in 2021 by BMS. Overseeing three state-of-the-art production facilities, Snehal is also closely involved in planning, development and construction of two additional facilities to continue expanding BMS’ global footprint. In addition, he has served as Site Head for Cell Therapy Manufacturing and is based in Seattle, WA. He started at BMS via the Juno Therapeutics acquisition in February 2018.

Prior to joining BMS, Snehal worked at Genentech/Roche for ~18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.

Snehal has a breadth of knowledge and experience including leadership roles in Technical Operations, Technology, Training, and Quality Assurance in Biologics, Small Molecules, and Cell Therapy. He is routinely sought out for his technical expertise, as well as his ability to collaborate and influence. He is a dynamic leader where he focuses on Inspirational Leadership and Development of his team.